Known targets — ChEMBL curated mechanism
CHRNA10CHRNA9GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3B
The experimentally established mechanism targets of Neramexane. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 known ✓ | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Neramexane SCHEMBL466073 | 0.96 | — | — | |
| SCHEMBL20756316 | 0.89 | — | — | |
| SCHEMBL339609 | 0.89 | — | — | |
| Neramexane SCHEMBL636426 | 0.78 | — | — | |
| Neramexane SCHEMBL637647 | 0.78 | — | — | |
| SCHEMBL30574160 | 0.76 | — | — | |
| SCHEMBL6032874 | 0.76 | — | — | |
| SCHEMBL11771323 | 0.76 | — | — | |
| SCHEMBL1133789 | 0.76 | — | — | |
| SCHEMBL20628690 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100076075-A1 | METHODS OF TREATING NEUROLOGICAL DISEASE USING ANTAGONISTS OF THE NMDA RECEPTOR COMPLEX | KOZACHUK WALTER E | 2010-03-25 | — | — | US | claimed |
| US-20220356226-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | UNIVERSIDAD DEL PAÍS VASCO / EUSKAL HERRIKO UNIBERTSITATEA (ES) | 2022-11-10 | — | — | US | disclosed |
| EP-4048400-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Universidad del País Vasco/Euskal Herriko Unibertsitatea (ES) | 2022-08-31 | — | — | EP | disclosed |
| US-20210169864-A1 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | MERZ PHARMA GMBH & CO KGAA (DE) | 2021-06-10 | — | — | US | disclosed |
| WO-2021078942-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | UNIVERSIDAD DEL PAÍS VASCO / EUSKAL HERRIKO UNIBERTSITATEA (ES) | 2021-04-29 | — | — | WO | disclosed |
| US-20160136144-A1 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2016-05-19 | — | — | US | disclosed |
| US-20140371260-A1 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | MERZ PHARMA GMBH & CO. KGAA (GE) | 2014-12-18 | — | — | US | disclosed |
| EP-2448908-B1 | METHOD OF PREPARING NERAMEXANE | MERZ PHARMA GMBH & CO KGAA (DE) | 2013-09-18 | — | — | EP | disclosed |
| EP-2448910-B1 | METHOD OF PREPARING NERAMEXANE | MERZ PHARMA GMBH & CO KGAA (DE) | 2013-05-15 | — | — | EP | disclosed |
| US-20120130130-A1 | METHOD OF PREPARING NERAMEXANE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2012-05-24 | — | — | US | disclosed |
| US-20040034055-A1 | Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists | MERZ PHARMA GMBH & CO. KGAA | 2004-02-19 | — | — | US | disclosed |
| US-6602862-B1 | 1-Amino-alkylcyclohexanes as trypanocidal agents | MERZ PHARMA GMBH & CO., KGAA (DE) | 2003-08-05 | — | — | US | disclosed |
| EP-1318800-A1 | 1-AMINO-ALKYLCYCLOHEXANES AS TRYPANOCIDAL AGENTS | MERZ + CO. GmbH & Co. (DE) | 2003-06-18 | — | — | EP | disclosed |
| EP-1303477-A2 | 1-AMINO-ALKYLCYCLOHEXANES AS 5-HT3- AND NEURONAL NICOTINICRECEPTOR ANTAGONISTS | MERZ + CO. GmbH & Co. (DE) | 2003-04-23 | — | — | EP | disclosed |
| CN-1374956-A | 1-cyclic amino-alkylcyclohexane compounds, pharmaceutical compositions thereof and their use as anticonvulsants | MERZ & CO GMBH & CO (DE) | 2002-10-16 | — | — | CN | disclosed |
| EP-1228052-A1 | 1-CYCLIC AMINO-ALKYLCYCLOHEXANE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE AS ANTICONVULSANTS | Merz Pharmaceuticals GmbH (DE) | 2002-08-07 | — | — | EP | disclosed |
| WO-2002024186-A1 | 1-AMINO-ALKYLCYCLOHEXANES AS TRYPANOCIDAL AGENTS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2002-03-28 | — | — | WO | disclosed |
| WO-2001098253-A2 | 1-AMINO-ALKYLCYCLOHEXANES AS 5-HT3 AND NEURONAL NICOTINICRECEPTOR ANTAGONISTS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2001-12-27 | — | — | WO | disclosed |
| WO-2001032640-A1 | 1-CYCLIC AMINO-ALKYLCYCLOHEXANE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE AS ANTICONVULSANTS | MERZ PHARMACEUTICALS GMBH (DE) | 2001-05-10 | — | — | WO | disclosed |
| US-6071966-A | ADMINISTERING TO LIVING ANIMAL 1-AMINOALKYLCYCLOHEXANE COMPOUND FOR ALLEVIATION OF CONDITION WHICH IS ALLEVIATED BY N-METHYL-D-ASPARTATE RECEPTOR ANTAGONIST, OR FOR ITS IMMUNOMODULATORY, ANTIMALARIAL, ANTI-BORNA VIRUS EFFECTS | MERZ + CO. GMBH & CO. (DE) | 2000-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371260-A1 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | ACHE, BACE1, CHRNE | GRIN1 24/4885GRIN2A 37/4885LMNA 1665/4885 |
| US-20160136144-A1 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | ACHE, PSEN1, BCHE | GRIN1 34/4885GRIN2A 40/4885LMNA 2080/4885 |
| US-20210169864-A1 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | ACHE, PSEN1, BCHE | GRIN1 34/4885GRIN2A 40/4885LMNA 2080/4885 |
| US-20120130130-A1 | METHOD OF PREPARING NERAMEXANE | DHPS, TOP1, NME1 | GRIN1 1003/4885GRIN2A 2120/4885LMNA 907/4885 |
| US-20040034055-A1 | Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists | GRIN3A, GRIN2A, HTR3A | GRIN1 7/4885GRIN2A 2/4885LMNA 3106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.